Literature DB >> 3065642

Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate.

W A Cassel, D R Murray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3065642

Source DB:  PubMed          Journal:  Nat Immun Cell Growth Regul        ISSN： 0254-7600


× No keyword cloud information.
  11 in total

Review 1.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

2.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

3.  Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.

Authors:  Pingdong Li; Chun-Hao Chen; Sen Li; Babak Givi; Zhenkun Yu; Dmitriy Zamarin; Peter Palese; Yuman Fong; Richard J Wong
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

4.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

5.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.

Authors:  Dmitriy Zamarin; Luis Martínez-Sobrido; Kaitlyn Kelly; Mena Mansour; Gang Sheng; Adam Vigil; Adolfo García-Sastre; Peter Palese; Yuman Fong
Journal:  Mol Ther       Date:  2009-02-10       Impact factor: 11.454

6.  Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Authors:  D Zamarin; A Vigil; K Kelly; A García-Sastre; Y Fong
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

Review 7.  Oncolytic viruses.

Authors:  J Nemunaitis
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

8.  Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo.

Authors:  Yulan Yan; Lijuan Jia; Jin Zhang; Yang Liu; Xuefeng Bu
Journal:  Oncol Lett       Date:  2014-09-25       Impact factor: 2.967

Review 9.  Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.

Authors:  Brendon J Coventry
Journal:  Ther Adv Vaccines Immunother       Date:  2019-08-01

Review 10.  Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.

Authors:  Dmitriy Zamarin; Jedd D Wolchok
Journal:  Mol Ther Oncolytics       Date:  2014-12-10       Impact factor: 7.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.